161 related articles for article (PubMed ID: 20682658)
1. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma.
Poth KJ; Guminski AD; Thomas GP; Leo PJ; Jabbar IA; Saunders NA
Mol Cancer Ther; 2010 Aug; 9(8):2430-9. PubMed ID: 20682658
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
Nör C; Zhang Z; Warner KA; Bernardi L; Visioli F; Helman JI; Roesler R; Nör JE
Neoplasia; 2014 Feb; 16(2):137-46. PubMed ID: 24709421
[TBL] [Abstract][Full Text] [Related]
3. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
4.
Nazari F; Oklejas AE; Nör JE; Pearson AT; Jackson TL
Cancer Res; 2020 Apr; 80(7):1451-1460. PubMed ID: 32041834
[TBL] [Abstract][Full Text] [Related]
5. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
6. IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.
Finkel KA; Warner KA; Kerk S; Bradford CR; McLean SA; Prince ME; Zhong H; Hurt EM; Hollingsworth RE; Wicha MS; Tice DA; Nör JE
Neoplasia; 2016 May; 18(5):273-281. PubMed ID: 27237319
[TBL] [Abstract][Full Text] [Related]
7. Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma.
Liu CW; Hua KT; Li KC; Kao HF; Hong RL; Ko JY; Hsiao M; Kuo ML; Tan CT
Mol Cancer Ther; 2017 Jul; 16(7):1421-1434. PubMed ID: 28265008
[TBL] [Abstract][Full Text] [Related]
8. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR
PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
11. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
12. 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.
Kerk SA; Finkel KA; Pearson AT; Warner KA; Zhang Z; Nör F; Wagner VP; Vargas PA; Wicha MS; Hurt EM; Hollingsworth RE; Tice DA; Nör JE
Clin Cancer Res; 2017 May; 23(10):2516-2527. PubMed ID: 27780858
[No Abstract] [Full Text] [Related]
13. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
Kaliyaperumal K; Sharma AK; McDonald DG; Dhindsa JS; Yount C; Singh AK; Won JS; Singh I
Redox Biol; 2015 Dec; 6():41-50. PubMed ID: 26177470
[TBL] [Abstract][Full Text] [Related]
14. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.
Yu CC; Tsai LL; Wang ML; Yu CH; Lo WL; Chang YC; Chiou GY; Chou MY; Chiou SH
Cancer Res; 2013 Jun; 73(11):3425-40. PubMed ID: 23548270
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation.
Noman ASM; Parag RR; Rashid MI; Islam S; Rahman MZ; Chowdhury AA; Sultana A; Jerin C; Siddiqua A; Rahman L; Nayeem J; Akther S; Baidya S; Shil RK; Rahman M; Shirin A; Mahmud R; Hossain SMI; Sumi SA; Chowdhury A; Basher SB; Hasan A; Bithy S; Aklima J; Chowdhury N; Hasan MN; Banu T; Chowdhury S; Hossain MM; Yeger H; Farhat WA; Islam SS
Cell Death Dis; 2020 Aug; 11(8):663. PubMed ID: 32814771
[TBL] [Abstract][Full Text] [Related]
16. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
Chang WM; Chang YC; Yang YC; Lin SK; Chang PM; Hsiao M
J Exp Clin Cancer Res; 2019 Jun; 38(1):245. PubMed ID: 31182137
[TBL] [Abstract][Full Text] [Related]
17. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma.
Ryumon S; Okui T; Kunisada Y; Kishimoto K; Shimo T; Hasegawa K; Ibaragi S; Akiyama K; Thu Ha NT; Monsur Hassan NM; Sasaki A
Oncol Rep; 2019 Dec; 42(6):2611-2621. PubMed ID: 31638244
[TBL] [Abstract][Full Text] [Related]
18. Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.
Ahmadinejad F; Bos T; Hu B; Britt E; Koblinski J; Souers AJ; Leverson JD; Faber AC; Gewirtz DA; Harada H
Mol Pharmacol; 2022 Mar; 101(3):168-180. PubMed ID: 34907000
[TBL] [Abstract][Full Text] [Related]
19. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
